Skandinaviska Enskilda Banken AB publ Purchases New Holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Skandinaviska Enskilda Banken AB publ purchased a new stake in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 48,200 shares of the company’s stock, valued at approximately $321,000.

A number of other institutional investors and hedge funds also recently modified their holdings of RXRX. Accel Wealth Management purchased a new stake in shares of Recursion Pharmaceuticals during the first quarter valued at approximately $41,000. CWM LLC grew its holdings in Recursion Pharmaceuticals by 1,888.7% during the first quarter. CWM LLC now owns 6,145 shares of the company’s stock valued at $41,000 after purchasing an additional 5,836 shares during the period. Daiwa Securities Group Inc. grew its holdings in Recursion Pharmaceuticals by 1,029.8% during the fourth quarter. Daiwa Securities Group Inc. now owns 6,903 shares of the company’s stock valued at $53,000 after purchasing an additional 6,292 shares during the period. Amundi grew its holdings in Recursion Pharmaceuticals by 69.6% during the fourth quarter. Amundi now owns 7,189 shares of the company’s stock valued at $57,000 after purchasing an additional 2,949 shares during the period. Finally, Tower Research Capital LLC TRC grew its holdings in Recursion Pharmaceuticals by 550.0% during the first quarter. Tower Research Capital LLC TRC now owns 14,944 shares of the company’s stock valued at $100,000 after purchasing an additional 12,645 shares during the period. 57.82% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Recursion Pharmaceuticals

In related news, CEO Christopher Gibson sold 65,015 shares of Recursion Pharmaceuticals stock in a transaction on Wednesday, August 2nd. The stock was sold at an average price of $13.04, for a total transaction of $847,795.60. Following the completion of the sale, the chief executive officer now owns 890,719 shares of the company’s stock, valued at $11,614,975.76. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other Recursion Pharmaceuticals news, COO Tina Marriott Larson sold 3,000 shares of the firm’s stock in a transaction dated Wednesday, May 31st. The stock was sold at an average price of $8.63, for a total transaction of $25,890.00. Following the sale, the chief operating officer now owns 424,160 shares in the company, valued at $3,660,500.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Christopher Gibson sold 65,015 shares of the firm’s stock in a transaction dated Wednesday, August 2nd. The shares were sold at an average price of $13.04, for a total value of $847,795.60. Following the sale, the chief executive officer now owns 890,719 shares in the company, valued at approximately $11,614,975.76. The disclosure for this sale can be found here. Over the last quarter, insiders sold 425,173 shares of company stock valued at $4,728,793. Company insiders own 19.96% of the company’s stock.

Recursion Pharmaceuticals Stock Up 0.9 %

Recursion Pharmaceuticals stock opened at $8.61 on Tuesday. Recursion Pharmaceuticals, Inc. has a one year low of $4.54 and a one year high of $16.75. The business has a fifty day moving average price of $10.28 and a 200-day moving average price of $8.28.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its quarterly earnings data on Tuesday, August 8th. The company reported ($0.38) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.38). The company had revenue of $11.02 million during the quarter, compared to analyst estimates of $10.43 million. Recursion Pharmaceuticals had a negative return on equity of 58.66% and a negative net margin of 520.11%. On average, research analysts predict that Recursion Pharmaceuticals, Inc. will post -1.46 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have weighed in on the company. KeyCorp increased their price objective on Recursion Pharmaceuticals from $12.00 to $15.00 in a report on Thursday, July 13th. Morgan Stanley began coverage on Recursion Pharmaceuticals in a report on Monday, May 22nd. They issued an “equal weight” rating and a $8.00 price target for the company. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $17.00 price target on shares of Recursion Pharmaceuticals in a report on Wednesday, August 9th. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat, Recursion Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $11.40.

Recursion Pharmaceuticals Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 1b/2 clinical trial to treat AXIN1 or APC mutant cancers.